Women's Health

Web Exclusives | March 12, 2021
Emerging evidence suggests PARP inhibitors have the potential to revolutionize the treatment of ovarian cancer.
Web Exclusives | March 12, 2021
Patients with advanced ovarian cancer may be eligible to receive frontline maintenance treatment with olaparib plus bevacizumab.
Web Exclusives | March 12, 2021
Ovarian cancer survivors frequently use adaptive and problem-focused coping strategies. During the COVID-19 pandemic, virtual technology has played a key role in shaping and determining these strategies.
Web Exclusives | March 12, 2021
Oral treatments for ovarian cancer can be taken at home, in a sequestered environment that may minimize undue risks for patients. Results from a randomized phase 3 study suggest oral PARP inhibitor therapy has improved efficacy when compared with intravenous chemotherapy.
Web Exclusives | March 12, 2021
Telemedicine may play a critical role by creating pathways for overcoming obstacles to healthcare access, particularly for breast cancer reconstruction.

Results 1 - 5 of 5

Subscribe to the Journal of Oncology Navigation & Survivorship®

To sign up for our print publication or e-newsletter, please enter your contact information below.

  • First Name *
    Last Name *
     
     
    Profession or Role
    Primary Specialty or Disease State
    Country
  • Please enter your mailing address.

    Address
     
    Address Line 2
    City
     
    State
    Zip Code